Corcept Therapeutics Inc
CORT71.880USD
-0.130-0.18%
Fechamento 07/11, 16:00（ET）Cotações atrasadas em 15 min
7.62BValor de mercado
56.85P/L TTM
Mais detalhes de Corcept Therapeutics Inc Empresa
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Informações da empresa
Código da empresaCORT
Nome da EmpresaCorcept Therapeutics Inc
Data de listagemApr 15, 2004
Fundado em1998
CEODr. Joseph K. Belanoff, M.D.
Número de funcionários500
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 15
Endereço101 Redwood Shores Parkway
CidadeREDWOOD CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94065
Telefone16506888803
Sitehttps://www.corcept.com/
Código da empresaCORT
Data de listagemApr 15, 2004
Fundado em1998
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.06K
+7.91%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.07K
--
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
5.49K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
35.90%
Investment Advisor
31.21%
Individual Investor
11.55%
Hedge Fund
8.44%
Research Firm
1.58%
Pension Fund
1.03%
Sovereign Wealth Fund
0.82%
Bank and Trust
0.51%
Family Office
0.06%
Other
8.89%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
722
96.66M
91.15%
-8.10M
2025Q1
746
97.45M
92.10%
-9.12M
2024Q4
673
98.29M
93.20%
-10.89M
2024Q3
625
101.82M
97.42%
-10.51M
2024Q2
589
103.22M
99.09%
-12.69M
2024Q1
582
107.51M
103.94%
+2.98M
2023Q4
555
98.31M
95.40%
-4.22M
2023Q3
540
96.45M
94.14%
-5.68M
2023Q2
523
94.35M
92.83%
-12.18M
2023Q1
528
100.60M
93.30%
-751.20K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
13.02M
12.28%
-611.02K
-4.48%
Mar 31, 2025
The Vanguard Group, Inc.
9.96M
9.39%
-133.66K
-1.32%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
7.74M
7.3%
-357.16K
-4.41%
Mar 31, 2025
Renaissance Technologies LLC
6.14M
5.79%
-55.57K
-0.90%
Mar 31, 2025
Baker (George Leonard Jr.)
5.31M
5.01%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.97M
3.75%
+142.78K
+3.73%
Mar 31, 2025
State Street Global Advisors (US)
3.40M
3.21%
-146.42K
-4.13%
Mar 31, 2025
Belanoff (Joseph K)
2.98M
2.81%
-40.35K
-1.34%
Apr 17, 2025
Wilson (James N)
2.35M
2.21%
+129.14K
+5.82%
Apr 17, 2025
Geode Capital Management, L.L.C.
2.26M
2.13%
+191.89K
+9.28%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
SPDR S&P Pharmaceuticals ETF
5.35%
Invesco S&P SmallCap Health Care ETF
5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
4.73%
Formidable ETF
4.13%
Invesco Pharmaceuticals ETF
3.79%
First Trust NYSE Arca Biotechnology Index Fund
3.55%
iShares U.S. Pharmaceuticals ETF
3.46%
Invesco S&P SmallCap Momentum ETF
3.09%
Invesco S&P SmallCap Quality ETF
2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
1.9%
Ver Mais
SPDR S&P Pharmaceuticals ETF
Proporção5.35%
Invesco S&P SmallCap Health Care ETF
Proporção5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção4.73%
Formidable ETF
Proporção4.13%
Invesco Pharmaceuticals ETF
Proporção3.79%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.55%
iShares U.S. Pharmaceuticals ETF
Proporção3.46%
Invesco S&P SmallCap Momentum ETF
Proporção3.09%
Invesco S&P SmallCap Quality ETF
Proporção2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção1.9%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
